WOW! To say "vast" would be understated. This effort is breathtaking. Since management was aware of impending patent grants, it was unable to publicly speak about them prematurely. It may explain why the company has consciencely decided to abandon further exploration of the lawless defiling of Amarin's rightful patents. Understanding at some point that the fix was in, they figured the best way to overcome circumstances out of it's control would be to rain down on the market, with so many innovative patents, that it would render any contender inputent to try the same playbook again. BPs love foreseeable trends they can craft and build around a pipeline of drugs. Can anyone point to a more plausible option that could catapult any BP ahead of the rest in the cardiovascular space?
ILT